Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.67 |
| ▸ | PARG | Q86W56 | 2/20 | 0.45 |
| ▸ | CMA1 | P23946 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992523 | 0.93 | GRM2 (0.61) | GRM2PARGCMA1GRIN1GRIN2B | |
| SCHEMBL14992606 | 0.88 | GRM2 (0.67) | GRM2PARGCMA1GRIN1GRIN2B | |
| SCHEMBL10146573 | 0.86 | GRM2 (0.59) | GRM2PARGCMA1GRIN1GRIN2B | |
| SCHEMBL10146618 | 0.84 | GRM2 (0.73) | GRM2GRIN1GRIN2B | |
| SCHEMBL14992683 | 0.84 | GRM2 (0.59) | GRM2PARGGRIN1GRIN2B | |
| SCHEMBL14991890 | 0.84 | GRM2 (0.56) | GRM2PARGCMA1GRIN1GRIN2B | |
| SCHEMBL14992865 | 0.82 | GRM2 (0.62) | GRM2PARGCMA1GRIN1GRIN2B | |
| SCHEMBL14992353 | 0.81 | GRM2 (0.58) | GRM2PARGGRIN1GRIN2B | |
| SCHEMBL14992389 | 0.81 | GRM2 (0.58) | GRM2PARGGRIN1GRIN2B | |
| SCHEMBL14992501 | 0.81 | GRM2 (0.76) | GRM2PARGGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | claimed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | claimed |
| EP-2603079-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Merck Sharp & Dohme Corp. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | claimed |
| WO-2012021382-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2012-02-16 | — | — | WO | claimed |
| EP-2603079-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME (US) | 2018-09-19 | — | — | EP | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993779-B2 | Positive allosteric modulators of MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143880-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRIA2, GRM1 | GRM2 1/4885PARG 4723/4885CMA1 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.